Why the study?
Does acarbose reduce the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance?
Population
Patients with impaired glucose tolerance (IGT)
Authors
Loading...
Supports acarbose in IGT to lower CVD and hypertension risk; extends glycemic data to cardiovascular outcomes.
Does acarbose reduce the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance?
Acarbose treatment may be associated with a reduced risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance.
Chiasson et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: